ProfileGDS5678 / 1460389_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 89% 89% 88% 88% 90% 90% 89% 89% 89% 89% 88% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0333389
GSM967853U87-EV human glioblastoma xenograft - Control 27.0087989
GSM967854U87-EV human glioblastoma xenograft - Control 37.0055889
GSM967855U87-EV human glioblastoma xenograft - Control 46.9843588
GSM967856U87-EV human glioblastoma xenograft - Control 56.956388
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.062590
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9477890
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.991589
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.9925789
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.99989
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9923189
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9961488
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0067889
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9979889